Cellectis SA (CLLS)vsRevolution Medicines Inc (RVMD)
CLLS
Cellectis SA
$3.06
-2.86%
HEALTHCARE · Cap: $307.87M
RVMD
Revolution Medicines Inc
$155.69
+3.11%
HEALTHCARE · Cap: $32.71B
Smart Verdict
WallStSmart Research — data-driven comparison
Cellectis SA generates 10023% more annual revenue ($75.11M vs $742,000). RVMD leads profitability with a 0.0% profit margin vs -89.5%. RVMD earns a higher WallStSmart Score of 24/100 (F).
CLLS
Avoid16
out of 100
Grade: F
RVMD
Avoid24
out of 100
Grade: F
Intrinsic Value Comparison
Multi-model valuation · Graham Formula
Margin of Safety
+89.8%
Fair Value
$35.97
Current Price
$3.06
$32.91 discount
Intrinsic value data unavailable for RVMD.
Key Strengths & Concerns
Side-by-side fundamental analysis
Key Strengths
No standout strengths identified
Conservative balance sheet, low leverage
Areas to Watch
0.0% earnings growth
Smaller company, higher risk/reward
Elevated debt levels
Weak financial health signals
0.0% earnings growth
0.0% margin — thin
Operating margin of 0.0%
Weak financial health signals
Comparative Analysis Report
WallStSmart ResearchBull Case : CLLS
CLLS has a balanced fundamental profile.
Bull Case : RVMD
The strongest argument for RVMD centers on Debt/Equity.
Bear Case : CLLS
The primary concerns for CLLS are EPS Growth, Market Cap, Debt/Equity. Debt-to-equity of 1.81 is elevated, increasing financial risk.
Bear Case : RVMD
The primary concerns for RVMD are EPS Growth, Profit Margin, Operating Margin.
Key Dynamics to Monitor
CLLS profiles as a turnaround stock while RVMD is a value play — different risk/reward profiles.
CLLS carries more volatility with a beta of 2.75 — expect wider price swings.
CLLS is growing revenue faster at -37.3% — sustainability is the question.
CLLS generates stronger free cash flow (-16M), providing more financial flexibility.
Bottom Line
RVMD scores higher overall (24/100 vs 16/100). CLLS offers better value entry with a 89.8% margin of safety. Both earn "Avoid" and "Avoid" ratings respectively — the choice depends on your investment horizon and risk tolerance.
This analysis is generated from publicly available financial data. Not financial advice.
Cellectis SA
HEALTHCARE · BIOTECHNOLOGY · USA
Cellectis SA, a clinical-stage biotechnology company, develops immuno-oncology products based on gene-edited T cells that express chimeric antigen receptors to attack and eradicate cancer cells. The company is headquartered in Paris, France.
Visit Website →Revolution Medicines Inc
HEALTHCARE · BIOTECHNOLOGY · USA
Revolution Medicines, Inc., a precision clinical-stage oncology company, is focused on developing therapies to inhibit borderline targets in RAS-addicted cancers. The company is headquartered in Redwood City, California.
Compare with Other BIOTECHNOLOGY Stocks
Want to dig deeper into these stocks?